Senesco Technologies, Inc. Announces Results Of Cohort 3 In SNS01-T Phase 1b/2a Trial
Published: Dec 09, 2013
BRIDGEWATER, N.J.--(BUSINESS WIRE)--Senesco Technologies, Inc. (“Senesco” or the “Company”) (OTCQB:SNTI) reported results of cohort 3 in its Phase 1b/2a clinical study of SNS01-T at the 55th American Society of Hematology Annual Meeting in New Orleans.
Help employers find you! Check out all the jobs and post your resume.